Addressing the Challenges in Downstream Processing Today and Tomorrow - Newer classes of biotherapies will require innovations in processing technology. - BioPharm International

ADVERTISEMENT

Addressing the Challenges in Downstream Processing Today and Tomorrow
Newer classes of biotherapies will require innovations in processing technology.


BioPharm International Supplements
Volume 24, Issue 4, pp. s8-s15

REFERENCES

1. C. Scott, Bioprocess Intl. 7 (10, Suppl.), (2009).

2. G. Walsh, Eur. J. Pharm. Biopharm. 55 (1), 3–10 (2003).

3. X. Wang et. al., mAbs. 1 (3), 254-267 (2009).

4. G. Jagschies et. al., BioPharm. Int. 19 (June Suppl.), 10–19 (2006).

5. J. R. Birch and A. J. Racher. Adv. Drug Deliv. Rev. 58 (5–6), 671-685 (2006).

6. B.D. Kelley, mAbs 1 (5), 1–10 (2009).

7. B.D. Kelley et.al., Biotechnol. Bioeng, 101 (3), 553–566 (2008).

8. J.L. Coffman, J.F. Kramarczyk, and B.D. Kelley, Biotechnol. Bioeng. 100 (4), 605–618 (2008).

9. B.D. Kelley et. al., Biotechnol. Bioeng. 100 (5), 950–963 (2008).

10. J. Glynn et. al., BioPharm. Int. 22 (October Suppl.), 15-19 (2009).

11. E.J. Suda, et. al., J. Chromatogr. A. 1216 (27), 5256–5264 (2009).

12. B. Kelley, Biotechnol. Prog. 23 (5), 995–1008 (2007).

13. G.R. Bolton, J. Basha, and D.P. LaCasse, Biotechnol. Prog. 26 (6), 1671–1677.

14. C. Winter, US patent 0237762 (2007).

15. G.R. Bolton, H. Araya, and A.W. Boesch, "Membrane Evaporation for Generating Highly Concentrated Protein Therapeutics" International Patent Application WO 2010/111378 A1.

16. M. Shamashkin et. al., Recovery of Biological Products XIV, (Lake Tahoe, CA 2010)

17. A.L. Nelson, E. Dhimolea, and J.M. Reichert, Nat. Rev. Drug. Discov. 9, 767–74 (2010).

18. G. Walsh, Nat. Biotechnol. 29 (9), 917–924 (2010).

19. C. Sheridan, Nat. Biotechnol. 28 (4), 307-310 (2010).

20. G. Walsh, BioPharma. Int. 23 (10), 1–8 (2009).

21. A.L. Nelson and J.M. Reichert, Nat. Biotechnol. 27 (4), 331–337 (2009).

22. M.D. Zolodz et. al., J. Chromatogr. A. 1217 (2), 225–234 (2010).

23. B.N. Violand. "Initial purification of inclusion bodies," in Protein Purification Applications, S. Roe, Ed. (Oxford University Press, Oxford, UK, 2nd ed. 2001), pp. 19–27.

24. J.J. Buckley, S.D. Hoeltzli, and G.V. Johnson, Biotechnol. Appl. Biochem. 56 (1), 27–34 (2010).

25. V. Dechavanne et. al., Protein Expr. Purif. 75 (2), 192–203 (2011).

26. S.C. Alley, N.M. Okeley, and P.D. Senter, Curr. Opin. Chem. Biol. 14 (4), 529–537 (2010).

27. C.F. McDonagh et. al., Protein Eng. Des. Sel. 19 (7), 299–307 (2006).

28. J.R. Junutula et. al., Nat. Biotech. 26 (8), 92–-932 (2009).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here